Other licensed pharmacological options : For patients unsuitable for or unable to tolerate Wegovy, alternatives include: Orlistat (lipase inhibitor that reduces fat absorption) Liraglutide 3mg (another GLP-1 receptor agonist, recommended by NICE TA664 for specific patient groups, though local NHS availability may vary) Consideration of bariatric surgery referral for eligible patients with severe obesity Medically supervised diets : If rapid weight loss is clinically indicated (e.g., pre-bariatric surgery), options include: Very low-calorie diets (800 kcal/day) under specialist supervision for up to 12 weeks Low-calorie diets (8001200 kcal/day) with appropriate nutritional support These differ fundamentally from HCG protocols as they provide adequate protein, vitamins, and minerals and are used within NHS-approved frameworks
Boosts immune system, aids in detoxification, and supports liver function
Among patients with T2D who had no prior history of CUD, semaglutide was associated with a significantly lower risk for incident CUD diagnosis compared with non-GLP-1RA anti-diabetes medications for a 12-month follow-up period (0.21% vs
NOTE: Women who are prescribed semaglutide have reported fewer sexual dysfunctions
Fewer digestive complaints